BrainsWay Hosts Virtual Analyst & Investor Day
BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 — BrainsWay Ltd. (NASDAQ: BWAY) has announced an exciting virtual Analyst & Investor Day is set for December 1, 2025. The event aims to showcase the company's innovative growth strategies and highlight the transformational effects of their noninvasive brain stimulation technology.
Insights from Expert Speakers
During this engaging virtual meeting, attendees will hear from prominent figures, including Owen Scott Muir, MD, DFAACAP, a co-founder and the Chief Medical Officer of Radial. Dr. Muir will share his clinical experiences with Deep TMS™, focusing on its benefits for various mental health conditions. He will delve into the significant needs that exist in mental health treatments today. Additionally, attendees will listen to Michael Gershenzon, the CEO of Stella MSO, a management services organization catering to over 20 mental health clinics in the U.S. and Israel. He will discuss the strategic partnership with BrainsWay and its investment in Stella, underscoring the collaboration's importance.
Understanding Deep TMS Technology
The highlight of the event will undoubtedly be an overview of BrainsWay's patented Deep Transcranial Magnetic Stimulation (Deep TMS) technology. This clinically validated procedure utilizes magnetic fields to stimulate neural networks in the brain, showing promise in treating conditions such as depression, obsessive-compulsive disorder, and smoking addiction. The event will also discuss the accelerated protocol's potential to enhance treatment outcomes.
Interactive Q&A Session
To ensure a comprehensive understanding, a live question-and-answer session will follow the formal presentations. This interactive segment will provide an opportunity for attendees to engage directly with the speakers, posing questions related to the content presented and any aspects of the company’s strategies.
About BrainsWay
BrainsWay is redefining the landscape of mental health treatment with its pioneering neurostimulation technologies. Founded in 2003, the company is dedicated to improving patient outcomes through its Deep TMS technology, which has gained FDA clearance for three major indications. These include major depressive disorder, obsessive-compulsive disorder, and smoking addiction, backed by substantial clinical evidence.
Ongoing Commitment to Mental Health Treatment
The commitment to enhance care and access to Deep TMS on a global scale continues amid ongoing clinical trials exploring the technology's applications for various psychiatric, neurological, and addiction disorders. BrainsWay is making significant strides in increasing awareness of and access to their innovative technologies, cementing their position as a leader in mental health solutions.
Outlined Contact Information
For inquiries related to this event or additional information about the company, please reach out to:
Ido Marom
Chief Financial Officer
Email: Ido.Marom@BrainsWay.com
Frequently Asked Questions
1. What is the purpose of BrainsWay's Investor Day?
The company aims to present its growth strategies and insights into their innovative Deep TMS treatment.
2. Who are the featured speakers at the event?
The event features Owen Scott Muir, MD, and Michael Gershenzon discussing their experiences with mental health treatments and strategies.
3. What technology does BrainsWay focus on?
BrainsWay specializes in Deep TMS, a noninvasive brain stimulation technology aimed at improving mental health conditions.
4. How can I participate in the Q&A session?
A live Q&A session will be held after the presentations, allowing attendees to engage with the speakers.
5. How can I learn more about BrainsWay?
Visit their official website at www.brainsway.com for more information.
